Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative ...

A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The ...

Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

The results indicated that simufilam failed to meet each of the ... If you suffered a loss in Cassava Sciences, Inc. during the relevant time frame, you have until February 10, 2025 to request ...

Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on Simufilam did not show a significant reduction in cognitive or functional ...

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences ... repeated statements of confidence in simufilam, Cassava's leading drug candidate ...

Company plans to add cognition and plasma biomarker monitoring to the open-label extension trials to gather additional long-term data on simufilam treatment. AUSTIN, Texas, July 30, 2024 (GLOBE ...